Patient stratification involves the use of biomarkers to create subsets within a patient population that provide more detailed information about how the patient will respond to a given drug (gene responders).  Stratification can be a critical component in transforming a clinical trial from a negative or neutral outcome to one with a positive outcome by identifying the subset of the population most likely to respond to a therapy.

GenetRx ^TM can be used to stratify patients using biomarkers (gene responders/non responders) to enrich a clinical trials population with one or more goals in mind including:

• Increasing the responder population
• Reducing the size, time & cost of a trial
• Improving overall results of your clinical trial

The use of even moderately effective biomarkers, e.g. 70% sensitivity and specificity, can dramatically improve trial outcome.

For more information relating to our capabilities in providing information to patient stratification programs, please click here